Apellis Pharmaceuticals, Inc.

NasdaqGS:APLS Stock Report

Market Cap: US$2.7b

Apellis Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Apellis Pharmaceuticals has been growing earnings at an average annual rate of 16.7%, while the Biotechs industry saw earnings growing at 23.2% annually. Revenues have been growing at an average rate of 44.9% per year. Apellis Pharmaceuticals's return on equity is 11.2%, and it has net margins of 4.4%.

Key information

16.75%

Earnings growth rate

26.58%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate44.91%
Return on equity11.21%
Net Margin4.43%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Aug 14

Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?

Jul 29
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?

Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers

May 09
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers
User avatar

SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally

SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.

The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%

Apr 11
The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%

Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Mar 14
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Apellis Pharmaceuticals: A Mixed Bag

Mar 05

Apellis: Saved By The October Data

Dec 25

There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise

Dec 15
There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Oct 18
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Oct 01

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Sep 27
Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 09

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12
Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30
What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30
It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

Revenue & Expenses Breakdown

How Apellis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:APLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 251,016455250
30 Jun 25755-2285040
31 Mar 25776-2245010
31 Dec 24781-1985010
30 Sep 24715-2505210
30 Jun 24629-3335450
31 Mar 24524-4175280
31 Dec 23397-5295010
30 Sep 23273-6064430
30 Jun 23185-6573760
31 Mar 23106-6913280
31 Dec 2275-6522770
30 Sep 22113-63423431
30 Jun 2297-63820231
31 Mar 2281-70218731
31 Dec 2167-7461770
30 Sep 21256-5201800
30 Jun 21251-4601710
31 Mar 21251-3601500
31 Dec 20251-34513921
30 Sep 201-536122-142
30 Jun 200-470104-91
31 Mar 200-42388-40
31 Dec 190-305670
30 Sep 190-22846173
30 Jun 190-19434152
31 Mar 190-15627128
31 Dec 180-128230
30 Sep 180-1092188
30 Jun 180-851768
31 Mar 180-641350
31 Dec 170-511040
30 Sep 170-39733
30 Jun 170-35629
31 Mar 170-30525
31 Dec 160-27423
30 Sep 160-29621
30 Jun 160-53719
31 Mar 160-50716
31 Dec 150-47614
30 Sep 150-41412
30 Jun 150-12410
31 Mar 150-1239

Quality Earnings: APLS has high quality earnings.

Growing Profit Margin: APLS became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: APLS has become profitable over the past 5 years, growing earnings by 16.7% per year.

Accelerating Growth: APLS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: APLS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (61.5%).

Return on Equity

High ROE: APLS's Return on Equity (11.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/31 21:38
End of Day Share Price 2025/10/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 33 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Colleen KusyBaird
Matthew LuchiniBMO Capital Markets Equity Research